SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 18, 2020
INMED PHARMACEUTICALS INC.
(Exact Name of Company as Specified in Charter)
(State or Other Jurisdiction
InMed Pharmaceuticals Inc.
Suite 310 - 815 W. Hastings Street,
|(Address of Principal Executive Offices)||(Zip Code)|
Companys telephone number, including area code: (604) 669-7207
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Name of each exchange
|Common Shares, no par value||INM||The Nasdaq Stock Market LLC|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
|Item 7.01|| |
Regulation FD Disclosure.
On November 18, 2020, the Company issued a press release announcing its collaboration with BayMedica Inc. A copy of the press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.
The information set forth in this Item 7.01, including Exhibit 99.1, is being furnished and shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities of that section. The information set forth in this Item 7.01, including Exhibit 99.1, shall not be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
|Item 9.01.|| |
Financial Statements and Exhibits.
The following exhibits shall be deemed to be furnished, and not filed:
|99.1||Press release, dated November 18, 2020.|
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|INMED PHARMACEUTICALS INC.|
|Date: November 18, 2020||By:|
|Eric A. Adams|
|President and Chief Executive Officer|
Suite 310-815 W. Hastings St.
Vancouver, BC, Canada V6C 1B4
InMed Pharmaceuticals and BayMedica Announce Collaboration for Manufacturing and Testing of Novel Cannabinoid Therapeutics
Vancouver, BC November 18, 2020 InMed Pharmaceuticals Inc. (InMed or the Company) (NASDAQ:INM; TSX:IN), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol (CBN), and BayMedica Inc., a company specializing in the design and manufacture of rare natural cannabinoids and cannabinoid analogs through biosynthesis and pharmaceutical chemistry, announced today they have entered into a broad reciprocal research collaboration to explore synergies between technologies owned by the two companies.
Under the terms of the Collaborative Research Agreement, BayMedica is being provided access to specific elements of InMeds proprietary IntegraSynTM platform for the production of cannabinoids. Specifically, BayMedica will assess the potential of one or more of InMeds high-efficiency enzyme gene sequences in BayMedicas systems for the production of the cannabinoids in BayMedicas catalogue.
InMed will undertake preclinical investigation of numerous therapeutic compounds selected from BayMedicas extensive library of proprietary cannabinoid analogs. Utilizing its validated assays and assessment criteria, InMed will also explore the therapeutic potential of specific analog compounds in selected disease models in the field of neuroprotection as compared to naturally occurring cannabinoids. BayMedica has a published patent application that encompasses thousands of new chemical entities based on cannabinoid analog structures.
Should the initial research phases of the individual projects defined under the agreement achieve positive and meaningful results, the Collaborative Research Agreement provides a mechanism to license the other partys technology.
About InMed: InMed Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of cannabinoid-based medications, initially focused on the therapeutic benefits of cannabinol (CBN) in diseases with high unmet medical need. The Company is dedicated to delivering new therapeutic alternatives to patients that may benefit from cannabinoid-based medicines. For more information, visit www.inmedpharma.com.
About BayMedica: BayMedica Inc. is a revenue stage biotechnology company leveraging synthetic biology and pharmaceutical chemistry to develop an efficient, scalable, and proprietary platform to produce high quality, rare cannabinoids for consumer applications and cannabinoid-derived new chemical entities for pharmaceutical applications. For more information visit www.baymedica.com.
|InMed Pharmaceuticals Inc.||BayMedica, Inc.|
|Brendan Payne, Director Investor Relations||Shane Johnson, MD, CEO|
|T: +1.604.669.7207||Tel: +1.858.354.7853|
|E: firstname.lastname@example.org||E: email@example.com|
Edison Advisors for InMed Pharmaceuticals
Joe Green/Laine Yonker
E: firstname.lastname@example.org / email@example.com
Cautionary Note Regarding Forward-Looking Information:
This news release contains forward-looking information and forward-looking statements (collectively, forward-looking information) within the meaning of applicable securities laws. Forward-looking information is based on managements current expectations and beliefs and is subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Forward-looking information in this news release includes statements about: leading the way in the clinical development of CBN; the exploration of synergies between technologies owned by the two companies; the assessment of the potential of one or more of InMeds high-efficiency gene sequences in BayMedicas system for the production of cannabinoids in BayMedicas catalogue; InMeds intention to undertake preclinical investigations of therapeutic compounds and to explore the therapeutic potential of specific analog compounds in selected disease models; and the potential to achieve positive results and the mechanism to license the other partys technology.
With respect to the forward-looking information contained in this news release, InMed has made numerous assumptions regarding, among other things: that InMed will lead the way in the clinical development of CBN; there will be synergies between technologies owned by the two companies; there will be one or more of InMeds high-efficiency gene sequences in BayMedicas system for the production of cannabinoids in BayMedicas catalogue; there will be benefits realized from InMed undertaking preclinical investigations of therapeutic compounds and to explore the therapeutic potential of specific analog compounds in selected disease models; and there may be positive results and the ability to license the other partys technology. While InMed considers these assumptions to be reasonable, these assumptions are inherently subject to significant business, economic, competitive, market and social uncertainties and contingencies.
Additionally, there are known and unknown risk factors which could cause InMeds actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein. Known risk factors include, among others: the outbreak and impact of COVID-19 may worsen; there may be little or no synergies at all to be realized; there may be little to no potential of one or more of InMeds high-efficiency gene sequences in BayMedicas systems for the production of cannabinoids in BayMedicas catalogues; there may be no therapeutic potential of specific analog compounds in selected disease models; there may be no positive results; and neither party may end up licensing the other partys technology. A more complete discussion of the risks and uncertainties facing InMed is disclosed in InMeds most recent Annual Information Form and other continuous disclosure filed with Canadian securities regulatory authorities on SEDAR at www.sedar.com.
All forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.
NEITHER THE TORONTO STOCK EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.